Current Status: April 2026
The peptide regulatory landscape in the United States is undergoing its most significant shift since the original Category 2 restrictions in late 2023. On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of the 19 peptides on the FDA's Category 2 restricted list would be reclassified to Category 1 — restoring legal compounding access through licensed pharmacies with a physician's prescription.
As of April 2026, the formal FDA reclassification has not been officially published. The announcement from HHS signals intent but does not constitute regulatory action. Until the FDA formally updates the Category 2 list, the legal status of these peptides for compounding remains technically unchanged. Do not source peptides from unregulated vendors based on the announcement alone.
The FDA is reportedly moving toward allowing compounding pharmacies to produce these peptides again. The formal publication is expected in the coming weeks, though no specific date has been confirmed. This tracker will be updated as official guidance is released.
Full Peptide Status Tracker
| Peptide | Expected Status | Primary Use | FDA Concern |
|---|---|---|---|
| BPC-157 | Returning | Tissue repair, gut healing, anti-inflammation | Immunogenicity, limited human data |
| Thymosin Alpha-1 | Returning | Immune modulation, oncology support | Immunogenicity risk |
| TB-500 (Thymosin Beta-4) | Returning | Muscle repair, flexibility, recovery | Immune reactions, limited safety data |
| AOD-9604 | Returning | Fat metabolism, weight management | Immunogenicity, lack of safety data |
| Ipamorelin | Returning | Growth hormone release, sleep, metabolism | GH axis modulation |
| Semax | Returning | Cognitive function, neuroprotection | Limited human safety data |
| Selank | Returning | Anxiolytic, cognitive enhancement | Limited human safety data |
| KPV | Returning | Anti-inflammatory, gut health | Limited safety information |
| MOTS-C | Returning | Metabolic health, exercise mimetic | Limited human data |
| Epithalon | Returning | Telomere regulation, anti-aging | Limited safety data |
| DSIP | Returning | Sleep regulation | Limited human safety data |
| GHK-Cu | Returning | Skin repair, wound healing, hair growth | Limited safety information |
| Kisspeptin | Returning | Reproductive hormone regulation | Hormonal axis modulation |
| VIP | Returning | Neuroprotection, anti-inflammatory | Limited safety data |
| Melanotan II | Restricted | Tanning, sexual function | Cardiovascular risk, melanoma concerns |
| GHRP-2 | Restricted | Growth hormone secretagogue | Cortisol and prolactin elevation |
| GHRP-6 | Restricted | Growth hormone secretagogue | Cortisol elevation, hunger stimulation |
| CJC-1295 | Restricted | Growth hormone release | Cardiac side effects reported |
| LL-37 (Cathelicidin) | Restricted | Antimicrobial, immune defense | Very limited human data |
All statuses shown are based on the February 27, 2026 HHS announcement and subsequent reporting. The formal FDA reclassification has not been published. Actual reclassification may differ from expectations. This table will be updated as official guidance is released.
Understanding FDA Categories
The FDA uses a category system to classify bulk drug substances for compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act. These categories determine whether a licensed compounding pharmacy can legally prepare a given substance.
Category 1 — Eligible for Compounding
Substances that licensed 503A compounding pharmacies can use to prepare individualized medications under a valid physician prescription. Category 1 status does not mean FDA-approved — it means the substance is available for pharmacy compounding within the existing regulatory framework. Quality, dosing, and monitoring remain the responsibility of the prescribing physician and compounding pharmacy.
Category 2 — Restricted (Safety Concerns)
Substances that the FDA has flagged for potential safety risks including immunogenicity, peptide-related impurities, or insufficient safety data. Category 2 substances are generally not permitted for routine compounding. This is the category that all 19 peptides were placed in during late 2023, and the category from which approximately 14 are expected to be removed.
Category 3 — Under Evaluation
Substances with insufficient information for full categorization. These are still being reviewed by the FDA and the Pharmacy Compounding Advisory Committee (PCAC).
Regulatory Timeline
Peptides Expected to Return to Legal Compounding
Approximately 14 peptides are expected to move from Category 2 to Category 1. These include some of the most widely used compounds in longevity, recovery, immune support, and metabolic optimization. The key expected returnees include:
Tissue Repair & Recovery: BPC-157, TB-500, GHK-Cu — these peptides have been central to injury recovery protocols. BPC-157 in particular has extensive preclinical evidence for gut healing, tendon repair, and anti-inflammatory effects.
Immune Modulation: Thymosin Alpha-1, KPV — used in oncology support and inflammatory conditions. Thymosin Alpha-1 has decades of international clinical use and is an approved drug in over 30 countries outside the US.
Growth Hormone Axis: Ipamorelin, Epithalon — used for sleep quality, metabolic support, and anti-aging protocols. Ipamorelin is considered one of the cleaner GH secretagogues with fewer side effects than alternatives.
Neuropeptides: Semax, Selank, DSIP, VIP — these address cognitive function, anxiety, sleep regulation, and neuroprotection. Semax and Selank are approved medications in Russia with established safety records.
Metabolic: AOD-9604, MOTS-C — fat metabolism and exercise mimetic peptides studied for metabolic health.
Reproductive: Kisspeptin — involved in reproductive hormone regulation with emerging clinical applications.
Peptides Expected to Remain Restricted
Approximately 5 peptides are expected to remain on the Category 2 list due to more substantive safety concerns or insufficient evidence:
Melanotan II — Associated with cardiovascular effects and potential melanoma risk. This is the peptide with the clearest safety signal among the 19.
GHRP-2 and GHRP-6 — Growth hormone releasing peptides with more complex side effect profiles including cortisol and prolactin elevation. The newer and cleaner alternative, Ipamorelin, is expected to return.
CJC-1295 — Reports of cardiac side effects have kept this on the restricted list. This is notable because CJC-1295/Ipamorelin stacks have been among the most popular growth hormone protocols.
LL-37 (Cathelicidin) — An antimicrobial peptide with very limited human safety data. Despite promising preclinical research, the evidence base is insufficient for the FDA's comfort level.
FDA-Approved Peptide Drugs (Separate Category)
Several peptide-based medications have gone through the full FDA approval process and are not affected by the Category 1/2 reclassification. These are separate from compounded peptides:
| Drug | Status | Brand Names | Indication |
|---|---|---|---|
| Semaglutide | FDA Approved | Ozempic, Wegovy, Rybelsus | Type 2 diabetes, weight management |
| Tirzepatide | FDA Approved | Mounjaro, Zepbound | Type 2 diabetes, weight management |
| Liraglutide | FDA Approved | Victoza, Saxenda | Type 2 diabetes, weight management |
| Leuprolide | FDA Approved | Lupron | Prostate cancer, endometriosis |
| Octreotide | FDA Approved | Sandostatin | Acromegaly, neuroendocrine tumors |
| Oxytocin | FDA Approved | Pitocin | Labor induction, postpartum hemorrhage |
| Insulin | FDA Approved | Humalog, Novolog, Lantus | Diabetes management |
FDA-approved peptide drugs like Semaglutide have strict compounding rules. Compounded versions are only legal under specific conditions (e.g., during an FDA-declared drug shortage) and using unapproved salt forms can result in severe legal consequences.
What This Means for Patients
If you've been using peptide therapy or have been waiting for access to be restored, here's what you need to know:
Don't source from unregulated vendors yet. Until the FDA formally publishes the reclassification, the safest path is to wait. Research chemical websites and overseas sources carry real risks of contamination, underdosing, and legal liability.
Work with a licensed physician. Even after reclassification, compounded peptides require a valid prescription from a licensed provider. This is non-negotiable — both for safety and legality.
Understand that reclassified does not mean approved. Category 1 peptides have not gone through the FDA's standard drug approval process. They lack standardized dosing guidelines, formal clinical indication approval, and large-scale safety data. Clinical oversight is essential.
Quality depends on the pharmacy. Not all compounding pharmacies are equal. Look for PCAB accreditation, USP 797 compliance, and pharmacies that provide third-party testing documentation for their products.
What This Means for Clinicians
Resume prescribing only after formal publication. The HHS announcement is not regulatory action. Wait for the FDA to formally update the Category 2 list before writing prescriptions for reclassified peptides.
Document your clinical rationale. Peptide therapy remains off-label even after reclassification. Thorough documentation of clinical rationale, patient consent, monitoring protocols, and sourcing from licensed pharmacies protects both you and your patients.
Source only from licensed 503A or 503B pharmacies. The reclassification specifically applies to licensed compounding pharmacies operating under physician prescription frameworks, not research chemical suppliers.
What This Means for Pharmacies
Prepare but don't jump the gun. Compounding pharmacies should begin preparing supply chains and quality protocols now, but should not begin compounding Category 2 substances until formal reclassification is published.
Quality controls matter more than ever. The FDA's original concerns about impurities and immunogenicity mean that pharmacies returning to peptide compounding will face heightened scrutiny. USP 797 sterile compounding standards, potency testing, and endotoxin testing should be considered baseline requirements.
Independent third-party testing builds trust. The market will reward pharmacies that can demonstrate quality through independent COA verification — particularly as patients and clinicians navigate the transition back to legal access.